Trial Profile

A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Setidegrasib (Primary) ; Carboplatin; Cetuximab; Cisplatin; Docetaxel; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel; Pembrolizumab; Pemetrexed
Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Astellas Pharma

Most Recent Events

02 Apr 2026 According to Florida Cancer Specialists & Research Institute media release, safety and efficacy of setidegrasib data from this trial published in New England Journal of Medicine.
01 Apr 2026 Planned End Date changed from 31 Dec 2027 to 31 Dec 2028.
01 Apr 2026 Planned primary completion date changed from 31 Dec 2027 to 31 Dec 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com